Editas Medicine
is a Massachusetts-based biotechnology company that develops and commercializes gene-edited therapeutics for the treatment of ocular diseases and cancer... Read moreEditas Medicine
is a Massachusetts-based biotechnology company that develops and commercializes gene-edited therapeutics for the treatment of ocular diseases and cancer... Read more
News
Sep 09, 2026
GlobeNewswire
Press Release: Editas Medicine : Editas Medicine Reports Inducement Grants to New Chief Medical Officer
Sep 04, 2026
Zacks
Editas Medicine: Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
Aug 07, 2026
Nasdaq
Editas Medicine: Editas Posts Narrower Loss In Q2, Expects Phase 1/2 Data For EDIT-401 In Q1 Of '27; Stock Up
Aug 06, 2026
Zacks
Editas Medicine: EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
Aug 05, 2026
centralcharts
Press Release: Editas Medicine : Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
Aug 05, 2026
Seeking Alpha
Editas Medicine: Editas Medicine GAAP EPS of -$0.15 beats by $0.12, revenue of $11.89M beats by $9.14M
May 26, 2026
Nasdaq
Editas Medicine: Editas Medicine Prices Up To $319.4 Million Public Offering
May 14, 2026
GlobalNewswire
Press Release: Editas Medicine : Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
May 06, 2026
Owler
Editas Medicine, Inc.: Editas Medicine's revenue had no change from Dec 2025 to Mar 2026
May 06, 2026
Zacks
Editas Medicine: EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Editas Medicine Competitors
1
2
3
4
5
6
7
8
9